ライフサイエンスコーパス: ranitidine

1 simulated gastric fluid 2 hours after adding ranitidine.

2 re on standard acid-suppressive therapy with ranitidine.

3 rmation yield of NDMA from chloramination of ranitidine.

4 e decomposition of the methylfuran moiety of ranitidine.

5 re chlorinated and hydroxylated analogues of ranitidine.

6 acid and 20 animals fed pH 7 formula without ranitidine.

7 e, and group 2 patients received intravenous ranitidine.

8 nytoin or carbamazepine), dexamethasone, and ranitidine.

9 Sucralfate was given to 47, and 49 received ranitidine.

10 d quinidine, drugs structurally unrelated to ranitidine.

11 mpromise or transfusion); all were receiving ranitidine.

12 e, patients received an intravenous bolus of ranitidine (0.5 mg/kg) followed by a continuous infusion

13 dation rate constant of the target pollutant ranitidine (1.06 ms(-1)) is 5-7 orders of magnitude fast

14 to BK induced by histamine was inhibited by ranitidine (10 microM).

15 with omeprazole at bedtime (P = NS); 4 with ranitidine, 150 mg at bedtime; and 3 with ranitidine, 30

16 time: placebo; additional omeprazole, 20 mg; ranitidine, 150 mg; and ranitidine, 300 mg.

17 through chloramination of the pharmaceutical ranitidine (3 muM).

18 d, placebo-controlled, double-blind trial of ranitidine 300 mg (orally twice daily) in subjects with

19 atment sequences and over 4 periods received ranitidine (300 mg) and placebo (randomized order) with

20 that included 18 healthy participants, oral ranitidine (300 mg), compared with placebo, did not sign

21 th ranitidine, 150 mg at bedtime; and 3 with ranitidine, 300 mg at bedtime (P < 0.05, ranitidine vs.

22 l omeprazole, 20 mg; ranitidine, 150 mg; and ranitidine, 300 mg.

23 The most commonly used agents for SUP were ranitidine (31%), famotidine (24%), sucralfate (24%), an

24 ell+/-SEM are reported: control 68.3+/-37.8; ranitidine 38.4 +/-94.2; lansoprazole 14.6+/-84.4; and o

25 nes that produce NDMA at high yields, namely ranitidine, 5-(dimethylaminomethyl)furfuryl alcohol, N,N

26 ated premedication regimen that consisted of ranitidine 50 mg, diphenhydramine 50 mg, and a single 20

27 razole (0.35 microg/mL); and d) control plus ranitidine (50 microg/mL).

28 etics of decomposition of the pharmaceutical ranitidine (a major precursor of NDMA) during chloramina

29 stric pH should be monitored and the dose of ranitidine adjusted accordingly.

30 , and the H2 histaminergic receptor agonist, ranitidine, also hindered recognition of the familiar ju

31 nd the H2 histaminergic receptor antagonist, ranitidine, also hindered the recognition of the familia

32 animals, either alone or in combination with ranitidine (an alcohol dehydrogenase inhibitor) while th

33 ncluding histamine H(2) receptor antagonist (ranitidine), analgesic (paracetamol), opiate (codeine),

34 Complete removal of ranitidine and cimetidine was achieved within 30 min of

35 The H(2) antagonists, ranitidine and famotidine, exhibit saturable absorptive

36 hloramine, nucleophilic substitution between ranitidine and monochloramine led to byproducts that are

37 a probable human carcinogen, was formed when ranitidine and nitrite were added to simulated gastric f

38 ies also reported the formation of NDMA when ranitidine and nitrite were added to simulated gastric f

39 ing contaminants such as the pharmaceuticals ranitidine and nizatidine.

40 statistically significant difference between ranitidine and placebo in 24-hour urinary excretion of N

41 an 24-hour NDMA urinary excretion values for ranitidine and placebo were 0.6 ng (IQR, 0 to 29.7) and

42 Ranitidine and tetrodotoxin abolished the inhibitory eff

43 ed with a minimum 3 mg/kg/day of intravenous ranitidine and the dose should be titrated to a gastric

44 gonists such as diphenhydramine, loratadine, ranitidine, and cimetidine, but has modest affinity for

45 fter exposure to the H2 receptor antagonist, ranitidine, and identified an antibody that reacted with

46 valsartan, irbesartan, losartan, metformin, ranitidine, and nizatidine.

47 Continuous infusion of ranitidine at 6.25 mg/hr (n = 9) or placebo (n = 11) for

48 omeprazole at bedtime with that of a dose of ranitidine at bedtime on residual nocturnal acid secreti

49 Ranitidine at bedtime reduced this parameter more, 5% wi

50 Regimen 2, ranitidine-bismuth-citrate + clarithromycin, was support

51 niramine, but not the H2 receptor antagonist ranitidine, blocks the effects of histamine in this prep

52 fect of the histamine-2-receptor antagonist, ranitidine, both at the cellular and mediator levels in

53 269 pg/mL (p < .05) in patients treated with ranitidine, but not in patients treated with placebo.

54 Treatment with ranitidine, but not placebo, was associated with a signi

55 Ranitidine caused increased DNA synthesis in PBMCs when

56 Oxidation of ranitidine, cimetidine, and ciprofloxacin was primarily

57 e continuous infusion, the mean steady-state ranitidine concentration associated with gastric pH > or

58 ease in urinary excretion of NDMA after oral ranitidine consumption.

59 received a citizen petition indicating that ranitidine contained the probable human carcinogen N-nit

60 and sertraline) and positive (omeprazole and ranitidine) control exposures.

61 fluid with different nitrite concentrations, ranitidine conversion to NDMA was not detected until nit

62 In addition, the petitioner proposed that ranitidine could convert to NDMA in humans; however, thi

63 he American population would need to consume ranitidine daily to match the NDMA loadings from laundry

64 Ranitidine decreases liver damage in Mdr2(-/-) (ATP bind

65 antihistamine treatments with pyrilamine or ranitidine did not impair tolerance and neither did IgE-

66 in this study may used to design an initial ranitidine dosage regimen that targets a gastric pH > or

67 The minimum ranitidine dose recommended in commonly used pediatric d

68 Gastric pH was determined at the end of the ranitidine dosing interval, 1 hr after the dose, and at

69 orothiazide (during the whole treatment) and ranitidine-fenofibrate (at short periods) in the BTV bio

70 The reaction between monochloramine and ranitidine followed second order kinetics and was acid-c

71 Most respondents selected ranitidine for ease of administration, famotidine becaus

72 24 hrs of scheduled intermittent intravenous ranitidine for stress ulcer prophylaxis were enrolled in

73 Decomposition of ranitidine formed different byproducts depending on the

74 In the ranitidine group, there were no significant elevations i

75 In both the sucralfate and ranitidine groups, clinical characteristics, number of d

76 cetate production by as much as 59%, whereas ranitidine had no significant effect.

77 ent of patients who received <3 mg/kg/day of ranitidine had poor gastric pH control as compared with

78 Ranitidine hydrochloride at 20 mg x kg(-1) x day(-1) was

79 patients, after treatment with cisapride or ranitidine in 2 patients, and after Nissen fundoplicatio

80 The pharmacokinetics of ranitidine in critically ill children are variable.

81 simulated gastric fluid 2 hours after adding ranitidine increased from 222 (12) ng at pH 5 to 11 822

82 Cimetidine, but not ranitidine, inhibits gastric alcohol metabolism in keepi

83 The findings do not support that ranitidine is converted to NDMA in a general, healthy po

84 Bedtime ranitidine is more effective than bedtime omeprazole on

85 These findings suggest that ranitidine is not converted to NDMA in gastric fluid at

86 servation implies that the N(CH3)2-moiety of ranitidine is transferred to NDMA without being chemical

87 the delta(2)H value of the N(CH3)2-group of ranitidine measured by quantitative deuterium nuclear ma

88 line or an antisecretory dose of omeprazole, ranitidine, or cimetidine, were intragastrically adminis

89 nificant difference between lansoprazole vs. ranitidine (p< .01), and omeprazole vs. ranitidine (p< .

90 vs. ranitidine (p< .01), and omeprazole vs. ranitidine (p< .05), and no significant difference betwe

91 Ranitidine pharmacokinetics were determined after a sing

92 sess the impact of multiple risk factors and ranitidine prophylaxis on the development of stress-rela

93 doses of the histamine 2-receptor antagonist ranitidine (RAN) and bacterial lipopolysaccharide (LPS)

94 of the tertiary amines, mianserin (MIA) and ranitidine (RAN), exhibiting similar compound specificit

95 yrilamine) and H3 (thioperamide) but not H2 (ranitidine) receptor antagonists at 10 microM.

96 els were significantly lower in placebo than ranitidine recipients.

97 cokinetic variables, the dose of intravenous ranitidine required to target 373 ng/mL as the average s

98 1 and 2 receptor antagonists pyrilamine and ranitidine, respectively, did not significantly alter NT

99 The description of ranitidine's pharmacokinetics and pharmacodynamics in th

100 finished drug products, including metformin, ranitidine, sartans and other drugs which caused multipl

101 These results indicate that ranitidine should be avoided where possible in the proph

102 Ranitidine should not be recommended for the treatment o

103 : valsartan/omeprazole; and ROR : valsartan/ranitidine) showed the highest signals after the recall

104 ly the parietal cell signal was inhibited by ranitidine, showing the absence of PAC1 on parietal cell

105 onsumption of a standard dose of the antacid ranitidine substantially increased NDMA and its chlorami

106 ESIGN, SETTING, AND PARTICIPANTS: One 150-mg ranitidine tablet was added to 50 or 250 mL of simulated

107 In this in vitro study of ranitidine tablets added to simulated gastric fluid with

108 hich is the background amount present in the ranitidine tablets.

109 The probe irreversibly inhibited ranitidine transport across Caco-2 cell monolayers and i

110 Infectious complications totaled 128 in the ranitidine-treated group and 50 in the sucralfate-treate

111 of infectious complications associated with ranitidine use and total infectious complications were a

112 Ranitidine use in severely injured patients is associate

113 Ranitidine use was associated with a 1.5-fold increased

114 ith ranitidine, 300 mg at bedtime (P < 0.05, ranitidine vs. placebo).

115 Gastric pH control with ranitidine was considered unsuccessful (poorly controlle

116 Of the drugs studied, ranitidine was used most often (15,627 neonates, 35 expo

117 The oral antihistamines pyrilamine and ranitidine were administered during tolerance induction

118 ble drugs, including metformin, sartans, and ranitidine were tested for NDMA, NDEA, and dimethylforma

119 nts enrolled in a randomized trial comparing ranitidine with sucralfate for gastritis prophylaxis wer